AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00947323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04003194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto Beans
Description: The intervention was 1/2 cup of pinto beans each day.
Study NCT04003194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Green Beans - control
Description: The control was 1/2 cup of green beans each day.
Study NCT01473992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otto Bock C-Leg
Description: Amputees' preferred prosthetic knee.
Study NCT01473992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otto Bock Genium
Description: Study knee.
Study NCT01758744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil Therapy
Description: Treprostinil: Inhaled prostanoid therapy
Study NCT01159522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB01A
Description: This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
Study NCT04730674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline mixed with xylocaine
Description: 10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
Study NCT03174782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
Study NCT03174782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
Study NCT03515447 — intervention group
Intervention type: OTHER
Intervention: Non interventional study
Study NCT00859976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneMaster coated acetabular shell.
Description: Bonemaster coated Exceed Acetabular Shell
Study NCT00859976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Coated Acetabular Shell
Description: Plasma HA coated Exceed Acetabular Shell
Study NCT03025932 — intervention group
Intervention type: PROCEDURE
Intervention: repair of giant hiatal hernia with mesh and anterior fundoplication
Study NCT01257399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol®
Description: 400 mg tablets
Study NCT01257399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 400mg tablets
Study NCT02912754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
Study NCT02912754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
Study NCT00298675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201 (iniparib)
Description: BSI-201 administered intravenously (IV), 2x weekly
Study NCT00298675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan administered weekly, IV.
Study NCT04502797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Patient Visit Assessment (ePVA)
Description: The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
Study NCT02150395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Study NCT02442193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Individual Placement and Support is a form of supported employment.
Study NCT04086238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU
Study NCT04086238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Capsules containing a combination of decitabine and THU
Study NCT01464619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Incredible Years Parenting Intervention
Description: The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
Study NCT01464619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Description: Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
Study NCT03153683 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
Study NCT02108899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval practice effect using descriptive stories and free-call tests without feedback
Description: In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts.
Study NCT02108899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval practice effect using descriptive stories and free-call tests without feedback
Description: In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts.
Study NCT01459835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media diet
Description: advice and tips and tools for healthy non violent TV viewing
Study NCT01459835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutritional intervention
Description: advice on healthy eating
Study NCT02611765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G intramuscular 7.2 million units
Description: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
Study NCT02611765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine penicillin G intramuscular 2.4 million units
Description: A single dose of intramuscular 2.4 million units of benzathine penicillin G
Study NCT02874833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
Study NCT02105519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (AdimFlu-S)
Description: Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
Study NCT00635986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100 mcg Fentanyl intravenous or epidural route
Study NCT01134263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, Subcutaneous (SC)
Study NCT01134263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
Description: 0.5 ml, SC
Study NCT01134263 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9%
Description: 0.5 ml, SC
Study NCT03148067 — intervention group
Intervention type: PROCEDURE
Intervention: Intramedullary nailing for fracture fixation
Study NCT04413942 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FB825
Description: Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
Study NCT04413942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer
Study NCT02591030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GEMCIS
Description: At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8.
Study NCT02591030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1
Study NCT03285165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
Description: patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
Study NCT03285165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10-70 mcg/kg/h propofol infusion.
Description: Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
Study NCT04796207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil (DPA+EPA 2:1 ratio) Capsules
Description: The Treatment Arm intervention consists of providing participants with 3 grams of DHA and EPA (2:1 weight ratio) in capsular form. In order to meet the required 3 grams of DHA and EPA, participants were given 6 capsules to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
Study NCT04796207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Safflower Oil Capsules
Description: The Placebo Arm intervention consists of providing participants with 3 grams of high-oleic safflower oil in a 1:1 allocation ratio in capsular form. In order to maintain the study masking, participants in the Placebo Arm were given 6 capsules (the same as the Treatment Arm) to be taken with meals (preferably breakfast, although capsules were provided at lunch when they couldn't be provided at breakfast). Capsules were given 3 times a week during the regular football season.
Study NCT02759835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
Study NCT02759835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Ablative Therapy (LAT)
Description: local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
Study NCT01313169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Reminder
Description: EMR reminders displayed
Study NCT01313169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR Reminder + Panel management
Description: EMR Reminder + Panel management
Study NCT01356563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical care
Description: Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
Study NCT04016272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
Study NCT04016272 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
Study NCT01586481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SANIDIAB
Description: off-loading shoe
Study NCT01586481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAROUK
Description: old shoe
Study NCT03617289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Study NCT03617289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D5W
Study NCT02309671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999049
Study NCT02309671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Study NCT04583644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopic Endoluminal Tracheal Occlusion Surgery
Description: Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation.
Study NCT03546816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg Serlopitant Tablets
Description: Serlopitant Tablets
Study NCT03546816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo Tablets
Study NCT04434001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate Human
Description: Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
Study NCT04434001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
Study NCT04434001 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
Study NCT03509246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin plus Bortezomib
Description: Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
Study NCT01126320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AnapnoGuard 100,
Description: Respiratory guard system during mechanical ventilation with routine mechanical ventilator
Study NCT01126320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: routine mechanical ventilator
Description: routine mechanical ventilation
Study NCT01096576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balapiravir [RO4588161]
Description: sequential cohorts receiving doses orally twice daily for 5 days
Study NCT01096576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally twice daily for 5 days
Study NCT04196543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: écho-doppler with ultrasonar Sonovue® injection
Description: During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later.
Study NCT02058836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Injection
Description: One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
Study NCT02058836 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
Study NCT00528671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
Study NCT00528671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
Study NCT00528671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenprocoumon
Description: The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
Study NCT00835185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8 (necitumumab)
Description: IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
Study NCT00835185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
Study NCT00835185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid (FA)
Description: FA 400 mg/m² IV infusion bolus injection
Study NCT00835185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
Study NCT01236352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-911543
Study NCT05846698 — intervention group
Intervention type: DRUG
Intervention: Luo-Bu-Fu-Ke-Bi-RI Pill
Description: 10 pills twice daily
Study NCT05846698 — intervention group
Intervention type: DRUG
Intervention: tibolone
Description: 2.5 mg once daily
Study NCT02858232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Study NCT02787083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Study NCT02031536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT02031536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT04718636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)
Description: Daily
Study NCT04718636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: Daily
Study NCT00322686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oglemilast
Description: Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
Study NCT00322686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Oglemilast
Description: Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 0.5 mg IV over 5 sec
Description: IV Prochlorperazine for bioavailability
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 0.625 mg
Description: Inhaled Staccato Prochlorperazine 0.625 mg
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 1.25 mg
Description: Inhaled Staccato Prochlorperazine 1.25 mg
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 2.5 mg
Description: Inhaled Staccato Prochlorperazine 2.5 mg